Page 1

● ● ● PRESS RELEASE Immatics Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase Immatics to initiate three expansion cohorts for IMA203 targeting PRAME : monotherapy , combination with checkpoint inhibitor , and next - generation ACT approach Cash and cash equivalents as well as other financial assets of $ 200.6 million¹ ( € 173.2 million ) as of September 30 , 2021 , funding company operations into 2023 Tuebingen , Germany and Houston , TX , November 16 , 2021 Immatics N.V. ( NASDAQ : IMTX ; " Immatics " ) , a clinical - stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies , today reported its financial results for the quarter ended September 30 , 2021 , and provided a business update on its progress over the reporting period . " The unprecedented objective response rate we have observed during early dose escalation in the ACTengine® IMA203 trial , encourages us to double down on our development strategy of our programs targeting PRAME , ” said Harpreet Singh , Ph.D. , CEO at Immatics . “ Following determination of target dose , we will start a concerted effort in early 2022 with multiple levers to pull to deliver durability of response . This will include deploying ACTengine® IMA203 ( 1 ) as monotherapy at target dose , ( 2 ) in combination with a checkpoint inhibitor , ( 3 ) as an efficacy enhanced next - gen TCR - T approach IMA203CD8 and ( 4 ) also now being able to offer IMA203 to patients with fewer lines of pre - treatments or less disease burden . We look forward to providing updates on these clinical outcomes throughout 2022. " Third Quarter 2021 and Subsequent Company Progress Adoptive Cell Therapy Programs ● ACTengine® IMA203 - On November 13 , Dr. Martin Wermke , coordinating investigator of the Phase 1 trial with IMA203 targeting PRAME , presented updated clinical data as a late breaking oral presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer ( SITC ) . The dose escalation phase of the trial for IMA203 is ongoing with dose level 3 completed at doses below 1 billion transduced cells in a heavily pre - treated patient population . In 15 out of 16 evaluable patients ( 94 % ) , treatment with IMA203 achieved disease control and tumor shrinkage was observed in 14 out of 16 patients ( 88 % ) . Objective responses ( partial responses according to RECIST 1.1 ) were observed in 8 out of 16 patients ( 50 % ) across multiple solid cancer indications . 8 out of 13 patients ( 62 % ) treated at dose Immatics Press Release November 16 , 2021 1 | 11